Literature DB >> 20436988

Efficacy of Orbscan II and Pentacam topographers by a repeatability analysis when assessing elevation maps in candidates to refractive surgery.

María Ximena Núñez1, Claudia Blanco.   

Abstract

INTRODUCTION: Anterior and posterior corneal elevations are measurements used to detect keratoconus suspects.
PURPOSE: To determine the efficacy of Orbscan II and Pentacam when assessing their elevation maps.
MATERIALS AND METHODS: The efficacy of the Orbscan II and Pentacam measuring the anterior and posterior corneal elevations were evaluated in a sample of 68 eyes. The concordance between the two devices and the coefficient of repeatability were measured following the parameters of the British Standard Institution by the Bland-Altman concordance analysis and the Lin concordance correlation coefficient.
RESULTS: The coefficient of repeatability at the point of maximum anterior elevation was 68.29% with the Orbscan and 24.20% with the Pentacam. The concordance correlation coefficient was 0.64 (CI 95%: 0.48-0.76) with the Orbscan and 0.94 with the Pentacam (CI 95%: 0.91-0.96). The coefficient of repeatability at the point of maximum posterior elevation was 38.7% with the Orbscan and 68.0% with the Pentacam. The concordance correlation coefficient was 0.69 with the Orbscan (CI 95%: 0.55-0.80) with a precision of 0.71 and an accuracy of 0.97, and 0.24 with the Pentacam (CI 95%: 0.00-0.45) with a precision of 0.24 and an accuracy of 0.99.
CONCLUSIONS: Measurement of the point of maximum posterior elevation is better with the Orbscan II and less precise with the Pentacam. The random error can be reduced by using the mean of three assessments and can serve as a guide in the search of diagnostic devices with minimum absolute relative error in all measurements.

Mesh:

Year:  2009        PMID: 20436988

Source DB:  PubMed          Journal:  Biomedica        ISSN: 0120-4157            Impact factor:   0.935


  1 in total

1.  Transepithelial Corneal Cross-Linking With Vitamin E-Enhanced Riboflavin Solution and Abbreviated, Low-Dose UV-A: 24-Month Clinical Outcomes.

Authors:  Ciro Caruso; Carmine Ostacolo; Robert L Epstein; Gaetano Barbaro; Salvatore Troisi; Decio Capobianco
Journal:  Cornea       Date:  2016-02       Impact factor: 2.651

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.